• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Novavax, Inc.

NASDAQ:NVAX

$1.27 $0.02 (1.60%)

REAL-TIME: Last trade at

RA Capital reports 9.9% passive stake in Novavax

NOVAVAX, Inc. Announces $12 Million Equity Offering

Novavax (NVAX) Reports Selling 10M Common at $1.22/Share

NOVAVAX, Inc. Announces $12 Million Equity Offering

NOVAVAX Launches Additional Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate

Novavax Launches Phase I Trial of Bird-Flu Vaccine

Novavax launches added Phase I Clinical Trial of A/H5N1 influenza vaccine

NOVAVAX Launches Additional Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate

Novavax, Inc. (NVAX) Misses Q1 EPS by 2c

Novavax reports Q1 EPS (6c), consensus (4c)

Earnings Watch For May 4 (AES, DUK, EXC, WCRX)

Novavax starts enrollment for its phase I bird flu vaccine trial

Trading Radar for 05/04: Novavax (NVAX), Federal Signal (FSS), Arcos Dorados (ARCO), U.S. Cellular (USM), Warner Chilcott (WCRX) Report

Novavax (NVAX) Begins Enrollment For A/H5N1 Bird Flu Candidate Trial

Novavax launches Phase I clinical trial of A/H5N1 influenza vaccine candidate

Novavax (NVAX) Commences Enrollment in A/H5N1 Vaccine Candidate Phase I

NOVAVAX to Report First Quarter 2012 Financial Results on May 4, 2012

Insider Buy At Novavax Spurs Speculation

Gaithersburg offers incentive to Novavax for move

NOVAVAX to Present at the 11th Annual Needham Healthcare Conference

Needham to host a conference

Novavax to present results from Phase 1 RSV study

NOVAVAX to Present Results From Phase I RSV Study at XIV International Symposium on Respiratory Viral Infections

NOVAVAX to Present at the 24th Annual ROTH Conference

NOVAVAX to Present at the 24th Annual ROTH Conference

Novavax reports Q4 EPS (3c), consensus (4c)

Novavax: discusses anticipated events for 2012

Novavax, Inc. (NVAX) Tops Q4 EPS by 7c

Novavax - Past year has been transformational for the company - NVAX

NOVAVAX Reports Fourth Quarter and 2011 Year-End Financial Results

NOVAVAX Appoints John A. Herrmann III, Vice President and General Counsel

Novavax launches Phase II clinical trial of seasonal influenza vaccine

Novavax (NVAX) Commences Enrollment in Quadrivalent Seasonal VLP Phase II

NOVAVAX Launches Phase II Clinical Trial of Seasonal Influenza Vaccine

NOVAVAX to Report 2011 Fourth-Quarter and Year-End Financial Results on March 9, 2012

NOVAVAX to Report 2011 Fourth-Quarter and Year-End Financial Results on March 9, 2012

NOVAVAX to Present at the 14th Annual Bio CEO & Investor Conference

NOVAVAX to Present at the 14th Annual Bio CEO & Investor Conference

NOVAVAX Appoints Mervyn L. Hamer, Vice President of Manufacturing

H1N1 spreading quickly in Mexico with 9 dead, Telegraph reports

See More Articles...